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Figure 1. This figure illustrates the specific criteria required for diagnosis of 
HLH  Figure 2. CT of the chest indicating lymphadenopathy Figure 3. Ultrasound 
indicating Splenomegaly
HLH is a clinically rare condition that is increasing in prevalence and is still significantly 
under recognized today. This case illustrates the necessity for early identification of HLH in 
the setting of predisposing conditions such as malignancy and initiation of treatment, 
especially in the setting of an unclear clinical picture delaying diagnosis. The high morbidity 
and mortality associated with this condition can be attributed to under recognition and the 
fulminant course of the disease, with the need for therapy to be initiated early for any 
reasonable attempt to provide a favorable outcome. While strides have been made recently 
in regards to treatment options increasing survival, this diagnosis remains devastating and 
much work remains to raise awareness and improve effectiveness of treatments. 
Malignancy Induced Hemophagocytic Lymphohistiocytosis
Shah, S MD, Patel, Jay MD, Osobamiro, O MD Department Of Internal 
Medicine Henry Ford Macomb, Clinton Township
Hemophagocytic Lymphohistiocytosis is a rare, aggressive and life threatening condition 
characterized by excessive immune activation. In view of a variable clinical presentation, 
lack of specificity of the clinical and laboratory findings and outcomes limited by delay in 
identification warrants discussion to help in this challenging diagnosis.
HLH comes in two forms, primary and secondary HLH. Here we discuss secondary HLH 
which by prevalence can be due to viral infections (29%), other infections (20%), 
malignancies (27%), rheumatologic disorder (7%) and immune deficiency syndromes (6%). 
Among the cases related to malignancy, most are due to hematologic malignancy. In children 
hematologic malignancy related HLH is associated with B-lymphoblastic leukemia, and in 
adults likely T cell lymphomas.
A 57-year-old female initially presented for a CT of the chest after failed 
outpatient treatment for pneumonia; initial imaging denoted diffuse 
lymphadenopathy, she followed up with Hematology/Oncology, having two fine 
needle aspirations with inconclusive results. 
Approximately 2 months later she presented to our ED with progressive 
shortness of breath, hypoxia and chest pain associated with significant fatigue 
and cough. Her initial physical examination was significant for only bilateral 
crackles at the lung bases. CT PE was performed which showed significant 
supraclavicular lymphadenopathy and subsegmental PE along with bibasilar 
infiltrates. At this point lactic acid was performed which was elevated, and she 
was diagnosed with PE, pneumonia and sepsis and admitted to the MICU and 
started on broad-spectrum antibiotics and heparin drip. 
While in the ICU General surgery was consulted for excisional biopsy of any 
reachable lymph node. Results from this biopsy showed Angioimmunoblastic T 
cell lymphoma with EBV driven polymorphous B cell lymphoproliferation. In 
post-op after the biopsy she became tachycardiac, tachypneiac and hypoxic. Over 
the next 5 days, she became significantly anemic, thrombocytopenic, febrile, 
hypercalcemic, hyperuricemic and hypofirbinogenemic, and developed 
significant splenomegaly of 17 cm with worsening lactic acidosis.
At this point HLH was considered and triglyceride levels along with ferritin and 
IL-3 (CD25) receptor were ordered. She was found to have significantly elevated 
ferritin and IL-2 along with high triglycerides and low fibrinogen. During this 
time she was also exhibiting tumor lysis syndrome with elevated LDH and uric 
acid, and became hemodynamically unstable; subsequently leading to the 
patients’ death.
HLH is a life-threatening condition due to ineffective immunity and uncontrolled hyper-inflammatory 
response. This is often a disease of the pediatric population, with the highest incidence in those <3 
months. However more and more it is being found in adults even as old as 70 years of age. It can often 
be triggered by infection, malignancy, and autoimmune disease. There are familial forms of this 
disease as well which result from defects in NK cells and cytotoxic T-cells. Hemophagocytosis refers 
to the literal phagocytotic engulfment of hematopoietic cells by macrophages activated in the bone 
marrow. Macrophages in HLH also secrete excessive amounts of cytokines leading to tissue damage 
and organ failure. Normally NK cells and cytotoxic T cells work to eliminate, damaged, stressed, or 
unregulated cells. In HLH however these cells fail to do so and the normal feedback regulation is lost 
resulting in continued macrophage activation and cytokine production. Triggers that have been 
identified are often viral in nature, and often related to EBV.
HLH normally presents as a febrile illness, with multiple organ systems involved. They can present 
with a confounding picture as fever of unknown origin, hepatitis, or even encephalitis or meningitis. 
Along with fever patients will often develop splenomegaly, bicytopenias, will have elevated LFTs and 
triglycerides. One important marker is ferritin, which is often over 500 in 94% of patients. The main 
cytopenia’s involved are anemia and thrombocytopenia with average hemoglobin around 7-8 and 
platelet counts around 70,000. Ferritin levels can often be increased in iron overload 
syndromes, sepsis, infections and liver failure, however at levels around 10,000 the specificity for 
HLH is 96%. Neurologic abnormalities are common in HLH, and can be variable from seizures, 
mental status changes, to ataxia. PRES syndrome can also be related to HLH. Pulmonary function and 
respiratory distress often occur with HLH, in and ARDS like fashion, which often requires mechanical 
ventilation.
The initial tests in HLH should be centered on that pathophysiology of the disease, including CBC w/ 
diff. coagulation studies, liver enzymes, Serum ferritin, LDH, and serum triglycerides. When clinical 
judgment leads you to a cause of HLH, further testing such as blood cultures, bone marrow 
evaluation, and imaging should be considered. Specialized testing can include Soluble IL-2 receptor, 
NK cell function, and flow cytometry. Five of the eight criteria for HLH are required for a diagnosis.
Treatment for patients that are critically ill with HLH is centered on HLH specific chemotherapy, 
which includes Etoposide and high dose steroids (dexamethasone), and intrathecal treatments if CNS 
involvement is found. Supportive treatment with transfusions for anemia and thrombocytopenia 
should be given as well to maintain platelet counts over 50,000. Long-term cure or the disease 
requires hematopoietic cell transplant, and in the case of malignancy related HLH would require 
allogenic transplant to stop recurrent HLH. The median survival of patient with HLH is 54% at 6 
years. Higher ferritin levels at diagnosis, and slow decline in ferritin during treatment is also a poor 
prognostic factor.
